Upload
stallioncode5009
View
34
Download
0
Tags:
Embed Size (px)
Citation preview
1. Alan M. Krensky; William M. Bennett; Flavio Vincenti. Immunosuppressants,
Tolerogens, and Immunostimulants. In: Burton LL, Lazo JS, Parker KL (eds),
Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edn.
New York. McGraw-Hill, 2006 [26].
2. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
3. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller CS
(eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
4. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
5. Katzung BG. Immunomodulating Agents. In: Basic and Clinical Pharmacology
9th Edition. New YorkMcGraw-Hill, 2007 [56].
6. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology in
General Medicine, 7th Edition, 2008 [27].
7. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-413.
8. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic and
clinical immunology 6th ed p. 1-14.
9. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
10.Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
11. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK, Nelson F,
Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of Disease 6 th
Edition. Philadelphia, Saunders Elsevier 2006 [6].
12.Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
13.Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System. In: A
Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007, p.1-
49.
14.Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial Series:
Rapid Learning Inc:RapidLearningCenter.com.
15.Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
16.Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, and
Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
17.Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
18.Ananthnarayan and Panicker. Structure and Functions of the Immune System.
In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan, 2005 [15].
19.Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
20. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy, Immunosuppressants
and Immunostimulants. In. Pharmacology and Pharmacotherapeutics, 22nd
Edn. Mumbai Popular Prakashan, 2009 [77].
21.Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology. London,
Mosby Elsevier, 2007 [5].
22.Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's Pharmacology
Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant drugs. Churchill
Livingstone, Elsevier 2011.
23. Scribed
24.Kat
25.Kat
26.Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen planus.
British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
27.Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen Planus – A
Review. Indian Journal Of Applied Research. March 2013, Vol 3, Issue 3. p289-
290.
28.Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds) Clinical and
Basic Immunodermatology. Springer, 05-Nov-2008 [32].
29.Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation and
Management. J. C. D. 68:494-9.
30.Gao F. Determination of corticosteroids in human plasma using micromass
LC/MS/MS. Apr 1, 2003.
31.Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition. Florida,
Taylo and Francis 2008. Alphabetical Presentation of Drugs.
32.Shanker
33.L3
34.Aberra NF, Lichtenstein GR. Review Article: Monitoring of Immunomodulators
in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2005; 21(4):307-319.
35.Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid
arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed. 1998; 65:267-
273.
36.Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral Biology and
Medicine 1993; 4(2):141-158.
37.C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the local
application of ciclosporine A on chronic erosive lichen planus of the oral cavity
38.xxx
39.Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570
patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
40.Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J Clin
Case Rep 3: (2013) 285
41.J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
42.Irene
43.Ison
44.James SH and David W. Kimberlin DW. Herpes Simplex Virus in Transplant
Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
45.Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial Virus.
Drugs R D. 2011 September; 11(3): 215–226.
46.Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
48.Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
49.Erbitux® (cetuximab) Prescribing Information, ImCloneSystems Incorporated,
New York, NY, USA, 2008.
50.S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head and
neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
51.R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
52.National Comprehensive Cancer Network, Head and Neck Cancers: National
Comprehensive Cancer Network Clinical Practice Guidelines in Oncology,
version 2, November 2008, http://www.nccn.org/professionals/physician
gls/PDF/ head-and-neck.pdf.
53.A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck cancer,”
Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
54.T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
55.P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
56.E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
57.National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
58.J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF, a
second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
59.R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
60.Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the treatment of
solid tumors other than melanoma and renal cell carcinoma,” Anti-Cancer
Drugs, vol.17, no.1, pp.1-12, 2006.
61.B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination nonviral
interleukin-2 gene immunotherapy for head and neck cancer: from bench top
to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
62.A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with perilymphatic
interleukin 2 in patients with resectable squamous cell carcinoma of the oral
cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97, 2002.
63.W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H. Chang,
“Phase I-II study of advanced head and neck squamous cell carcinoma patients
treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
64.S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination cisplatin,
5-fluorouracil, and interferon-alpha in the treatment of advanced esophageal
carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
65.S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
66.C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
67.J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J. Brandwein,
and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic, induces
maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
68.M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53 peptide
presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
69.T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De Leo,
“p53 as an immunotherapeutic target in head and neck cancer,” Advances in
Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
70.Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
71.M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-cell
responses to human CEA from patients immunized with recombinant avipox-
CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
47.J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
Alan M. Krensky; William M. Bennett; Flavio Vincenti. Immunosuppressants,
Tolerogens, and Immunostimulants. In: Burton LL, Lazo JS, Parker KL (eds),
Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edn.
New York. McGraw-Hill, 2006 [26].
48.Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
49.Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller CS
(eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
50.Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
51.Katzung BG. Immunomodulating Agents. In: Basic and Clinical Pharmacology
9th Edition. New YorkMcGraw-Hill, 2007 [56].
52.Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology in
General Medicine, 7th Edition, 2008 [27].
53.Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-413.
54.Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic and
clinical immunology 6th ed p. 1-14.
55.Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
56.Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
57. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK, Nelson F,
Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of Disease 6 th
Edition. Philadelphia, Saunders Elsevier 2006 [6].
58.Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
59.Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System. In: A
Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007, p.1-
49.
60.Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial Series:
Rapid Learning Inc:RapidLearningCenter.com.
61.Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
62.Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN, and
Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
63.Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
64.Ananthnarayan and Panicker. Structure and Functions of the Immune System.
In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan, 2005 [15].
65.Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
66. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy, Immunosuppressants
and Immunostimulants. In. Pharmacology and Pharmacotherapeutics, 22nd
Edn. Mumbai Popular Prakashan, 2009 [77].
67.Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology. London,
Mosby Elsevier, 2007 [5].
68.Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's Pharmacology
Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant drugs. Churchill
Livingstone, Elsevier 2011.
69. Scribed
70.Kat
71.Kat
72.Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen planus.
British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
73.Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen Planus – A
Review. Indian Journal Of Applied Research. March 2013, Vol 3, Issue 3. p289-
290.
74.Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds) Clinical and
Basic Immunodermatology. Springer, 05-Nov-2008 [32].
75.Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation and
Management. J. C. D. 68:494-9.
76.Gao F. Determination of corticosteroids in human plasma using micromass
LC/MS/MS. Apr 1, 2003.
77.Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition. Florida,
Taylo and Francis 2008. Alphabetical Presentation of Drugs.
78.Shanker
79.L3
80.Aberra NF, Lichtenstein GR. Review Article: Monitoring of Immunomodulators
in Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2005; 21(4):307-319.
81.Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in rheumatoid
arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed. 1998; 65:267-
273.
82.Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral Biology and
Medicine 1993; 4(2):141-158.
83.C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the local
application of ciclosporine A on chronic erosive lichen planus of the oral cavity
84.xxx
85.Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570
patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
86.Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J Clin
Case Rep 3: (2013) 285
87.J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
88.Irene
89.Ison
90.James SH and David W. Kimberlin DW. Herpes Simplex Virus in Transplant
Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
91.Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial Virus.
Drugs R D. 2011 September; 11(3): 215–226.
92.Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
72.Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
73.Erbitux® (cetuximab) Prescribing Information, ImCloneSystems Incorporated,
New York, NY, USA, 2008.
74.S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head and
neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
75.R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
76.National Comprehensive Cancer Network, Head and Neck Cancers: National
Comprehensive Cancer Network Clinical Practice Guidelines in Oncology,
version 2, November 2008, http://www.nccn.org/professionals/physician
gls/PDF/ head-and-neck.pdf.
77.A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck cancer,”
Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
78.T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
79.P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
80.E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
81.National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
82.J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF, a
second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
83.R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
84.Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the treatment of
solid tumors other than melanoma and renal cell carcinoma,” Anti-Cancer
Drugs, vol.17, no.1, pp.1-12, 2006.
85.B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination nonviral
interleukin-2 gene immunotherapy for head and neck cancer: from bench top
to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
86.A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with perilymphatic
interleukin 2 in patients with resectable squamous cell carcinoma of the oral
cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97, 2002.
87.W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H. Chang,
“Phase I-II study of advanced head and neck squamous cell carcinoma patients
treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
88.S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination cisplatin,
5-fluorouracil, and interferon-alpha in the treatment of advanced esophageal
carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
89.S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
90.C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
91.J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J. Brandwein,
and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic, induces
maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
92.M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53 peptide
presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
93.T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De Leo,
“p53 as an immunotherapeutic target in head and neck cancer,” Advances in
Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
94.Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
95.M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-cell
responses to human CEA from patients immunized with recombinant avipox-
CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
96.J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
93.Alan M. Krensky; William M. Bennett; Flavio Vincenti. Immunosuppressants,
Tolerogens, and Immunostimulants. In: Burton LL, Lazo JS, Parker KL (eds),
Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th edn.
New York. McGraw-Hill, 2006 [26].
94.Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
95.Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller CS
(eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
96.Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
97.Katzung BG. Immunomodulating Agents. In: Basic and Clinical Pharmacology
9th Edition. New YorkMcGraw-Hill, 2007 [56].
98.Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology in
General Medicine, 7th Edition, 2008 [27].
99.Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-413.
100. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
101. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
102. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
103. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
104. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
105. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
106. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
107. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
108. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
109. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
110. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
111. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
112. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
113. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
114. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
115. Scribed
116. Kat
117. Kat
118. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
119. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
120. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
121. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
122. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
123. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
124. Shanker
125. L3
126. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
127. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
128. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
129. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
130. xxx
131. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
132. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
133. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
134. Irene
135. Ison
136. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
137. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
138. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
97.Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
98.Erbitux® (cetuximab) Prescribing Information, ImCloneSystems Incorporated,
New York, NY, USA, 2008.
99.S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head and
neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
100. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
101. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
102. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
103. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
104. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
105. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
106. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
107. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
108. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
109. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
110. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
111. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
112. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
113. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
114. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
115. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
116. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
117. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
118. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
119. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
120. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
121. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
139. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
140. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
141. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
142. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
143. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
144. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
145. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
146. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
147. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
148. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
149. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
150. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
151. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
152. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
153. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
154. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
155. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
156. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
157. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
158. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
159. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
160. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
161. Scribed
162. Kat
163. Kat
164. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
165. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
166. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
167. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
168. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
169. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
170. Shanker
171. L3
172. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
173. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
174. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
175. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
176. xxx
177. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
178. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
179. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
180. Irene
181. Ison
182. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
183. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
184. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
122. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
123. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
124. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
125. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
126. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
127. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
128. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
129. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
130. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
131. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
132. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
133. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
134. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
135. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
136. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
137. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
138. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
139. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
140. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
141. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
142. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
143. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
144. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
145. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
146. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
185. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
186. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
187. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
188. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
189. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
190. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
191. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
192. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
193. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
194. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
195. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
196. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
197. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
198. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
199. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
200. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
201. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
202. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
203. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
204. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
205. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
206. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
207. Scribed
208. Kat
209. Kat
210. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
211. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
212. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
213. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
214. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
215. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
216. Shanker
217. L3
218. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
219. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
220. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
221. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
222. xxx
223. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
224. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
225. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
226. Irene
227. Ison
228. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
229. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
230. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
147. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
148. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
149. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
150. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
151. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
152. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
153. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
154. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
155. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
156. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
157. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
158. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
159. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
160. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
161. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
162. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
163. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
164. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
165. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
166. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
167. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
168. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
169. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
170. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
171. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
231. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
232. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
233. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
234. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
235. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
236. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
237. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
238. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
239. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
240. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
241. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
242. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
243. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
244. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
245. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
246. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
247. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
248. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
249. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
250. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
251. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
252. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
253. Scribed
254. Kat
255. Kat
256. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
257. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
258. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
259. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
260. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
261. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
262. Shanker
263. L3
264. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
265. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
266. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
267. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
268. xxx
269. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
270. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
271. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
272. Irene
273. Ison
274. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
275. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
276. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
172. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
173. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
174. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
175. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
176. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
177. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
178. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
179. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
180. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
181. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
182. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
183. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
184. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
185. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
186. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
187. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
188. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
189. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
190. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
191. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
192. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
193. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
194. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
195. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
196. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
277. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
278. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
279. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
280. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
281. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
282. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
283. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
284. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
285. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
286. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
287. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
288. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
289. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
290. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
291. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
292. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
293. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
294. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
295. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
296. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
297. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
298. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
299. Scribed
300. Kat
301. Kat
302. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
303. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
304. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
305. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
306. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
307. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
308. Shanker
309. L3
310. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
311. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
312. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
313. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
314. xxx
315. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
316. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
317. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
318. Irene
319. Ison
320. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
321. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
322. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
197. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
198. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
199. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
200. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
201. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
202. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
203. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
204. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
205. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
206. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
207. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
208. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
209. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
210. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
211. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
212. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
213. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
214. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
215. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
216. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
217. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
218. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
219. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
220. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
221. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
323. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
324. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
325. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
326. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
327. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
328. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
329. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
330. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
331. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
332. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
333. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
334. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
335. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
336. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
337. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
338. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
339. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
340. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
341. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
342. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
343. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
344. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
345. Scribed
346. Kat
347. Kat
348. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
349. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
350. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
351. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
352. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
353. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
354. Shanker
355. L3
356. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
357. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
358. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
359. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
360. xxx
361. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
362. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
363. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
364. Irene
365. Ison
366. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
367. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
368. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
222. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
223. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
224. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
225. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
226. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
227. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
228. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
229. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
230. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
231. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
232. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
233. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
234. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
235. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
236. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
237. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
238. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
239. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
240. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
241. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
242. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
243. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
244. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
245. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
246. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
369. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
370. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
371. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
372. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
373. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
374. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
375. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
376. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
377. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
378. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
379. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
380. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
381. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
382. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
383. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
384. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
385. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
386. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
387. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
388. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
389. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
390. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
391. Scribed
392. Kat
393. Kat
394. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
395. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
396. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
397. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
398. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
399. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
400. Shanker
401. L3
402. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
403. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
404. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
405. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
406. xxx
407. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
408. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
409. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
410. Irene
411. Ison
412. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
413. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
414. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
247. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
248. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
249. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
250. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
251. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
252. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
253. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
254. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
255. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
256. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
257. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
258. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
259. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
260. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
261. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
262. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
263. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
264. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
265. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
266. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
267. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
268. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
269. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
270. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
271. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
415. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
416. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
417. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
418. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
419. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
420. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
421. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
422. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
423. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
424. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
425. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
426. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
427. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
428. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
429. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
430. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
431. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
432. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
433. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
434. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
435. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
436. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
437. Scribed
438. Kat
439. Kat
440. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
441. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
442. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
443. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
444. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
445. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
446. Shanker
447. L3
448. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
449. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
450. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
451. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
452. xxx
453. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
454. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
455. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
456. Irene
457. Ison
458. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
459. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
460. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
272. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
273. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
274. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
275. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
276. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
277. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
278. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
279. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
280. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
281. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
282. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
283. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
284. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
285. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
286. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
287. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
288. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
289. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
290. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
291. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
292. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
293. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
294. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
295. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
296. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
461. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
462. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
463. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
464. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
465. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
466. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
467. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
468. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
469. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
470. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
471. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
472. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
473. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
474. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
475. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
476. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
477. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
478. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
479. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
480. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
481. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
482. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
483. Scribed
484. Kat
485. Kat
486. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
487. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
488. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
489. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
490. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
491. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
492. Shanker
493. L3
494. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
495. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
496. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
497. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
498. xxx
499. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
500. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
501. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
502. Irene
503. Ison
504. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
505. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
506. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
297. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
298. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
299. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
300. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
301. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
302. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
303. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
304. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
305. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
306. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
307. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
308. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
309. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
310. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
311. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
312. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
313. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
314. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
315. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
316. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
317. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
318. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
319. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
320. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
321. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
507. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
508. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
509. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
510. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
511. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
512. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
513. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
514. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
515. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
516. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
517. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
518. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
519. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
520. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
521. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
522. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
523. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
524. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
525. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
526. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
527. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
528. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
529. Scribed
530. Kat
531. Kat
532. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
533. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
534. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
535. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
536. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
537. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
538. Shanker
539. L3
540. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
541. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
542. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
543. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
544. xxx
545. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
546. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
547. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
548. Irene
549. Ison
550. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
551. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
552. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
322. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
323. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
324. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
325. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
326. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
327. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
328. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
329. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
330. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
331. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
332. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
333. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
334. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
335. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
336. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
337. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
338. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
339. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
340. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
341. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
342. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
343. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
344. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
345. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
346. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
553. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
554. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
555. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
556. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
557. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
558. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
559. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
560. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
561. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
562. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
563. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
564. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
565. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
566. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
567. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
568. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
569. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
570. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
571. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
572. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
573. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
574. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
575. Scribed
576. Kat
577. Kat
578. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
579. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
580. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
581. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
582. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
583. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
584. Shanker
585. L3
586. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
587. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
588. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
589. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
590. xxx
591. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
592. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
593. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
594. Irene
595. Ison
596. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
597. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
598. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
347. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
348. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
349. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
350. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
351. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
352. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
353. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
354. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
355. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
356. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
357. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
358. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
359. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
360. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
361. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
362. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
363. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
364. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
365. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
366. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
367. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
368. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
369. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
370. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
371. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
599. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
600. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
601. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
602. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
603. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
604. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
605. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
606. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
607. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
608. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
609. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
610. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
611. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
612. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
613. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
614. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
615. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
616. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
617. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
618. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
619. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
620. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
621. Scribed
622. Kat
623. Kat
624. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
625. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
626. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
627. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
628. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
629. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
630. Shanker
631. L3
632. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
633. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
634. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
635. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
636. xxx
637. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
638. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
639. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
640. Irene
641. Ison
642. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
643. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
644. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
372. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
373. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
374. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
375. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
376. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
377. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
378. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
379. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
380. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
381. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
382. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
383. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
384. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
385. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
386. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
387. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
388. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
389. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
390. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
391. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
392. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
393. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
394. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
395. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
396. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
645. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
646. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
647. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
648. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
649. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
650. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
651. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
652. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
653. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
654. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
655. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
656. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
657. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
658. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
659. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
660. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
661. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
662. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
663. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
664. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
665. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
666. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
667. Scribed
668. Kat
669. Kat
670. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
671. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
672. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
673. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
674. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
675. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
676. Shanker
677. L3
678. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
679. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
680. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
681. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
682. xxx
683. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
684. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
685. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
686. Irene
687. Ison
688. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
689. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
690. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
397. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
398. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
399. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
400. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
401. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
402. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
403. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
404. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
405. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
406. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
407. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
408. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
409. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
410. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
411. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
412. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
413. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
414. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
415. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
416. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
417. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
418. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
419. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
420. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
421. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
691. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
692. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
693. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
694. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
695. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
696. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
697. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
698. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
699. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
700. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
701. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
702. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
703. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
704. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
705. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
706. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
707. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
708. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
709. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
710. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
711. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
712. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
713. Scribed
714. Kat
715. Kat
716. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
717. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
718. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
719. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
720. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
721. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
722. Shanker
723. L3
724. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
725. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
726. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
727. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
728. xxx
729. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
730. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
731. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
732. Irene
733. Ison
734. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
735. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
736. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
422. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
423. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
424. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
425. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
426. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
427. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
428. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
429. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
430. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
431. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
432. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
433. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
434. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
435. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
436. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
437. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
438. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
439. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
440. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
441. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
442. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
443. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
444. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
445. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
446. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
737. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
738. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
739. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
740. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
741. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
742. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
743. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
744. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
745. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
746. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
747. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
748. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
749. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
750. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
751. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
752. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
753. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
754. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
755. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
756. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
757. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
758. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
759. Scribed
760. Kat
761. Kat
762. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
763. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
764. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
765. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
766. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
767. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
768. Shanker
769. L3
770. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
771. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
772. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
773. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
774. xxx
775. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
776. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
777. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
778. Irene
779. Ison
780. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
781. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
782. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
447. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
448. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
449. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
450. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
451. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
452. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
453. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
454. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
455. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
456. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
457. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
458. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
459. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
460. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
461. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
462. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
463. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
464. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
465. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
466. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
467. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
468. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
469. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
470. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
471. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
783. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
784. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
785. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
786. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
787. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
788. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
789. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
790. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
791. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
792. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
793. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
794. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
795. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
796. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
797. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
798. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
799. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
800. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
801. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
802. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
803. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
804. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
805. Scribed
806. Kat
807. Kat
808. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
809. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
810. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
811. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
812. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
813. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
814. Shanker
815. L3
816. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
817. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
818. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
819. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
820. xxx
821. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
822. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
823. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
824. Irene
825. Ison
826. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
827. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
828. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
472. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
473. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
474. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
475. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
476. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
477. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
478. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
479. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
480. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
481. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
482. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
483. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
484. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
485. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
486. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
487. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
488. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
489. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
490. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
491. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
492. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
493. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
494. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
495. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
496. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
829. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
830. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
831. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
832. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
833. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
834. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
835. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
836. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
837. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
838. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
839. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
840. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
841. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
842. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
843. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
844. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
845. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
846. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
847. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
848. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
849. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
850. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
851. Scribed
852. Kat
853. Kat
854. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
855. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
856. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
857. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
858. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
859. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
860. Shanker
861. L3
862. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
863. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
864. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
865. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
866. xxx
867. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
868. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
869. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
870. Irene
871. Ison
872. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
873. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
874. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
497. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
498. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
499. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
500. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
501. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
502. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
503. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
504. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
505. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
506. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
507. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
508. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
509. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
510. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
511. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
512. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
513. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
514. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
515. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
516. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
517. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
518. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
519. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
520. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
521. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
875. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
876. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
877. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
878. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
879. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
880. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
881. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
882. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
883. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
884. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
885. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
886. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
887. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
888. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
889. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
890. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
891. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
892. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
893. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
894. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
895. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
896. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
897. Scribed
898. Kat
899. Kat
900. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
901. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
902. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
903. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
904. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
905. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
906. Shanker
907. L3
908. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
909. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
910. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
911. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
912. xxx
913. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
914. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
915. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
916. Irene
917. Ison
918. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
919. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
920. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
522. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
523. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
524. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
525. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
526. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
527. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
528. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
529. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
530. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
human monocyte-derived dendritic cells with native tumor DNA induces
antigen-specific T-cell responses in vitro,” Cancer Biology and Therapy, vol. 5,
no. 12, pp. 1624-1631, 2006.
531. National Institutes of Health. ClinicalTrials.gov, November 2008,
http://www.clinicaltrials.gov/ct2/home.
532. J.C.Hu,R.S.Coffin, C. J. Davis, et al., “A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex virus expressing granulocyte
macrophage colony-stimulating factor,” Clinical Cancer Research, vol. 12, no.
22,pp. 6737–6747, 2006.
533. R. S. Coffin, M. Hingorani, I. McNeish, et al., “Phase I/II trial of
OncoVEXGM−CSF combined with radical chemoradiation (CRT) in patients with
newly diagnosed node-positive stage III/IV head and neck cancer (HNC),”
Journal of Clinical Oncology, vol. 25, no. 18S, p. 14095, 2007.
534. Grande, J. L. Firvida, V. Navas, and J. Casal, “Interleukin-2 for the
treatment of solid tumors other than melanoma and renal cell carcinoma,”
Anti-Cancer Drugs, vol.17, no.1, pp.1-12, 2006.
535. B. W. O’Malley Jr., D. Li, S. J. McQuone, and R. Ralston, “Combination
nonviral interleukin-2 gene immunotherapy for head and neck cancer: from
bench top to bedside,” Laryngoscope, vol. 115, no. 3, pp. 391–404, 2005.
536. A. De Stefani, G. Forni, R. Ragona, et al., “Improved survival with
perilymphatic interleukin 2 in patients with resectable squamous cell
carcinoma of the oral cavity and oropharynx,” Cancer, vol. 95, no. 1, pp. 90–97,
2002.
537. W. J. Richt Smeier, W. W. Koch, W. P. McGui re, M. E. Poole, and E. H.
Chang, “Phase I-II study of advanced head and neck squamous cell carcinoma
patients treated with recombinant human interferon gamma,” Archives of
Otolaryngology, vol.116, no. 11, pp. 1271–1277, 1990.
538. S. Bazarbashi,M. Rahal,M. A. Raja, et al., “A pilot trial of combination
cisplatin, 5-fluorouracil, and interferon-alpha in the treatment of advanced
esophageal carcinoma,” Chemotherapy, vol. 48, no. 4, pp. 211–216, 2002.
539. S. G. Urba, A. A. Forastiere, G. T. Wolf, and P. C. Amrein, “Intensive
recombinant interleukin-2 and alpha-interferon therapy in patients with
advanced head and neck squamous carcinoma,” Cancer, vol. 71, no. 7, pp.
2326–2331, 1993.
540. C. M. Van Herpen, M. Looman, M. Zonneveld, et al., “Intratumoral
administration of recombinant human interleukin 12 in head and neck
squamous cell carcinoma patients elicits a T-Helper 1 profile in the
locoregional lymph nodes,” Clinical Cancer Research, vol. 10, no. 8, pp. 2626–
2635, 2004.
541. J. E. Egan, K. J. Quadrini, F. Santiago-Schwarz, J. W. Hadden, H. J.
Brandwein, and K. L. Signorelli, “IRX-2, a novel in vivo immunotherapeutic,
induces maturation and activation of human dendritic cells in vitro,” Journal of
Immunotherapy, vol. 30, no. 6, pp. 624–633, 2007.
542. M. Eura, K. Chikamatsu, and F. Katsura, “A wild-type sequence p53
peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize
squamous cell carcinomas of the head and neck,” Clinical Cancer Research, vol.
6, no. 3, pp. 979–986, 2000.
543. T. K. Hoffmann, H. Bier, A. D. Donnenberg, T. L. Whiteside, and A. B. De
Leo, “p53 as an immunotherapeutic target in head and neck cancer,” Advances
in Otorhinolaryngology, vol. 62, pp. 151–160, 2005.
544. Y. Ueda, K. Shimizu, and T. Itoh, “Induction of peptide-specific immune
response in patients with primary malignant melanoma of the esophagus after
immunotherapy using dendritic cells pulsed with MAGE peptides,” Japanese
Journal of Clinical Oncology, vol. 37, no. 2, pp. 140–145, 2007.
545. M.Zhu, J.Marshall, D.Cole, J.Schlom and K.Y.Tsang, “Specific cytolytic T-
cell responses to human CEA from patients immunized with recombinant
avipox-CEA vaccine,” Clinical Cancer Research, vol. 6, no. 1, pp. 24–33, 2000.
546. J. L. Marshall, J. L. Gulley, P. M. Arlen, et al., “Phase I study of sequential
vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with
vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-
stimulating factor, in patients with carcinoembryonic antigen-expressing
carcinomas,” Journal of Clinical Oncology, vol. 23,no. 4, pp. 720–731, 2005.
921. Alan M. Krensky; William M. Bennett; Flavio Vincenti.
Immunosuppressants, Tolerogens, and Immunostimulants. In: Burton LL, Lazo
JS, Parker KL (eds), Goodman & Gilman's The Pharmacological Basis of
Therapeutics. 11th edn. New York. McGraw-Hill, 2006 [26].
922. Philip D. Hall, Jean-Michel Goust, and Gabriel Virella. Medical immunology. Immune system modulators, 5th edi .473-97.
923. Kafrawy AH. Immune System. In: Bricker SL, Langlais RP, Craig S. Miller
CS (eds), Oral Diagnosis, Oral Medicine, and Treatment Planning. 2nd Edn.
Ontario, BC Decker, 2002 [17].
924. Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus
interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest
Dermatol. 2002 Feb; 118(2):366-71.
925. Katzung BG. Immunomodulating Agents. In: Basic and Clinical
Pharmacology 9th Edition. New YorkMcGraw-Hill, 2007 [56].
926. Wolff, Klaus; Goldsmith, Lowell A.; Katz et al. Fitzpatrick's Dermatology
in General Medicine, 7th Edition, 2008 [27].
927. Bellanti JA. (Ed). A Text book of Immunology III. Saunders 1985. p336-
413.
928. Daniel P Stites, John D Stobo, J Vivian wells editors. A Text book of Basic
and clinical immunology 6th ed p. 1-14.
929. Jowetz, Melnick and Adelberg, editors. A Text book of Medical Microbiology 24th ed. p.145.
930. Gupta S.K. Immune System. In: A Text book of Essential Immunology. New Delhi Avichal Publishing Company, 2011. p.1-34
931. Kumar VK. Diseases of the Immune System. In: Kumar VK, Abbas AK,
Nelson F, Aster JC Robins (eds). Robbins and Cotran Pathoologic Basis of
Disease 6th Edition. Philadelphia, Saunders Elsevier 2006 [6].
932. Atkinson JC, Imanguli MM, Challacombe S. Immunologic Diseases. In: Greenberg MS, Glick M, Ship J. (eds) Burket’s Oral Medicine, 11th edn. Hamilton BC Decker Inc. 2008 [18].
933. Kuby, Kindt, Goldyby, Osborn (eds), Overview of the Immune System.
In: A Text book of Immunology. 6th ed. Massachusetts, W. H. Freeman, 2007,
p.1-49.
934. Huang W, Graham A, James E, Kale A. Immunology Learning Tutorial
Series: Rapid Learning Inc:RapidLearningCenter.com.
935. Sonia Gawande, PhDRoitt I, Brostoff J, Male D. Immunotherapy. In:
Immunology 6th Edn, London, Mosby 2001. P297 - 301.
936. Xue H, Kovanen PE, Pise-Masison CA, Berg M, Radovich MF, Brady JN,
and Leonard WJ. IL-2 negatively regulates IL-7 receptor α chain expression in
activated T lymphocytes
937. Heiserman DL. Immune Response. In: Introduction to Immunology.
SweetHaven Publishing Services. waybuilder.net /sweethaven /medtech
/immunology.
938. Ananthnarayan and Panicker. Structure and Functions of the Immune
System. In: Textbook of Microbiology 7th Edn. New Delhi Orient Blackswan,
2005 [15].
939. Kumar P and Clark M. The Immune System. In: Kumar & Clark’s Clinical
Medicine 8th Edn. Elsevier 2008.
940. Satoskar RS, Rege NN, Bhandarkar SD. Immunotherapy,
Immunosuppressants and Immunostimulants. In. Pharmacology and
Pharmacotherapeutics, 22nd Edn. Mumbai Popular Prakashan, 2009 [77].
941. Mark Kester M, Kent E. Vrana KE. Elsevier's Integrated Pharmacology.
London, Mosby Elsevier, 2007 [5].
942. Rang HP, Ritter JM, Dale MM, Flower R. (eds) in: Rang & Dale's
Pharmacology Ed 6, Chapter 26 Anti-inflammatory and immunosuppressant
drugs. Churchill Livingstone, Elsevier 2011.
943. Scribed
944. Kat
945. Kat
946. Crispian Scully a,∗, Marco Carrozzo Oral mucosal disease: Lichen
planus. British Journal of Oral and Maxillofacial Surgery 46 (2008) 15–21.
947. Koneru J, Mahalakshmi MP and Naik R. Management of Oral lichen
Planus – A Review. Indian Journal Of Applied Research. March 2013, Vol 3,
Issue 3. p289-290.
948. Hengge UR. Topical Corticosteroids. In: Gaspari A, Tyring SK (eds)
Clinical and Basic Immunodermatology. Springer, 05-Nov-2008 [32].
949. Edwards PC, Kelsch R. (2002). Oral Lichen Planus: Clinical Presentation
and Management. J. C. D. 68:494-9.
950. Gao F. Determination of corticosteroids in human plasma using
micromass LC/MS/MS. Apr 1, 2003.
951. Ebadi M. Desk Reference of Clinical Pharmacology, Second Edition.
Florida, Taylo and Francis 2008. Alphabetical Presentation of Drugs.
952. Shanker
953. L3
954. Aberra NF, Lichtenstein GR. Review Article: Monitoring of
Immunomodulators in Inflammatory Bowel Disease. Aliment Pharmacol Ther.
2005; 21(4):307-319.
955. Sibilia J, Liote F, Mariette X. Lymphoproliferative disorders in
rheumatoid arthritis patients on low-dose methotrexate. Rev Rhum Engl Ed.
1998; 65:267-273.
956. Eisen D. The therapy of Oral Lichen Planus. Critical Reviews in Oral
Biology and Medicine 1993; 4(2):141-158.
957. C Francès, S Boisnic, S Etienne, and H Szpirglas. (1988). Effect of the
local application of ciclosporine A on chronic erosive lichen planus of the oral
cavity
958. xxx
959. Silverman S Jr, Gorsky M, Lozada-Nur F. A prospective follow-up study
of 570 patients with oral lichen planus: persistence, remission, and malignant
association. Oral Surg Oral Med Oral Pathol. 1985 Jul; 60(1):30-4.
960. Simbli MA. Erythema Multiforme: Challenging Diagnosis for Internist. J
Clin Case Rep 3: (2013) 285
961. J D Meyer, M Degraeve, J Clarysse, F De Loose, and W Peremans Irene.
Levamisole in aphthous stomatitis: evaluation of three regimens. Br Med J.
1977 March 12; 1(6062): 671–674.
962. Irene
963. Ison
964. James SH and David W. Kimberlin DW. Herpes Simplex Virus in
Transplant Recipients. In: Infectious Disease and Antimicrobial Agents.
www.antimicrobe.org/t02.asp.
965. Bracht M, Basevitz D and Paulley R. Impact of Respiratory Syncytial
Virus. Drugs R D. 2011 September; 11(3): 215–226.
966. Stavem K, Bjørtuft Ø, Borgan Ø, Geiran O, Boe J. Lung transplantation in
patients with chronic obstructive pulmonary disease in a national cohort is
without obvious survival benefit. J Heart Lung Transplant. 2006 Jan; 25(1):75-
84.
547. Schubert MM, Sullivan KM, Morton TH, Izutsu KT, Peterson, Flournoy N,
Truelove EL, Sale GE, Buckner D, Storb R and Thomas ED. American Cancer
Society, Cancer Facts & Figures 2008, American Cancer Society, Atlanta, Ga,
USA, 2008.
548. Erbitux® (cetuximab) Prescribing Information, ImCloneSystems
Incorporated, New York, NY, USA, 2008.
549. S. C. Lee, A. L´opez-Albaitero, and R. L. Ferris, “Immunotherapy of head
and neck cancer using tumor antigen-specific monoclonal antibodies,” Current
Oncology Reports, vol. 11, no.2, pp. 156-162, 2009.
550. R. Haddad, L. Wirth, and M. Posner, “Emerging drugs for head and neck
cancer,” Expert Opinion on Emerging Drugs, vol.11, no. 3, pp. 461-467, 2006.
551. National Comprehensive Cancer Network, Head and Neck Cancers:
National Comprehensive Cancer Network Clinical Practice Guidelines in
Oncology, version 2, November 2008,
http://www.nccn.org/professionals/physician gls/PDF/ head-and-neck.pdf.
552. A.A.Wu, K.J.Niparko and S.I.Pai, “Immunotherapy for head and neck
cancer,” Journal of Biomedical Science, vol. 15, no. 3, pp. 275-289, 2008.
553. T. L. Whiteside, “Immunobiology and immunotherapy of head and neck
cancer,” Current Oncology Reports, vol. 3, no.1, pp. 46-55, 2001.
554. P. Comoli, P. Pedrazzoli, R. Maccario, et al., “Cell therapy of stage IV
nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted
cytotoxic T lymphocytes,” Journal of Clinical Oncology, vol. 23, no. 35, pp.
8942-8949, 2005.
555. E. Artusio, B. Hathaway, J. Stanson, and T. L. Whiteside, “Transfection of
556.